1. Home
  2. SACH vs CING Comparison

SACH vs CING Comparison

Compare SACH & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$0.96

Market Cap

57.5M

Sector

Real Estate

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.42

Market Cap

59.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
CING
Founded
2010
2012
Country
United States
United States
Employees
27
14
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.5M
59.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SACH
CING
Price
$0.96
$5.42
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$2.00
$34.50
AVG Volume (30 Days)
251.6K
372.7K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
19.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.00
N/A
Revenue Next Year
$6.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$3.16
52 Week High
$1.45
$11.89

Technical Indicators

Market Signals
Indicator
SACH
CING
Relative Strength Index (RSI) 40.91 55.86
Support Level $0.91 $4.94
Resistance Level $1.12 $6.67
Average True Range (ATR) 0.03 0.40
MACD 0.00 0.10
Stochastic Oscillator 28.42 53.33

Price Performance

Historical Comparison
SACH
CING

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: